NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
Clinical Trials
9 trialsNCT00439608 2020-02-17
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Brown University
Phase 2 Completed
NCT00398398 2020-01-07
Study of XELOX With Cetuximab in Advanced Gastric Cancer
Asan Medical Center
Phase 2 Completed
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT00857246 2015-12-07
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
NYU Langone Health
Phase 2 Completed
NCT00397904 2015-11-25
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00130689 2015-05-14
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00678535 2014-07-21
EXPAND
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT01388790 2013-11-20
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Merck KGaA, Darmstadt, Germany
Phase 2 Completed